

(Translation)



**Minutes of the Extraordinary General Meeting of Shareholders No. 1/2019
of
E for L Aim Public Company Limited**

Date, Time and Venue of the Meeting

The Meeting was arranged on Tuesday, 5 November 2019 at 09.30 a.m., at Krungthep Ballroom, the Royal City Hotel, 800 Boromratchonni Rd., Bangbamru, Bangphlat, Bangkok.

Directors and Executives Attending the Meeting

- | | | |
|----|----------------------------|---|
| 1. | Mr. Preecha Nuntnarumit | Chairman of the Board, Chief Executive Officer |
| 2. | Mr. Jackrit Lohajaroensub | Director |
| 3. | Mr. Jitkasem Sangsingkeo | Director |
| 4. | Mr. Sampan Hunpayon | Independent Director, Member of the Audit Committee |
| 5. | Mr. Pipat Yingseree | Independent Director, Member of the Audit Committee |
| 6. | Mr. Apirak Kanchanakongkha | Acting Chief Finance Officer |

Equal to 85.7143% of the total number of directors (Seven persons)

Directors and Executives Not Attending the Meeting

- | | | |
|----|----------------------------|---|
| 1. | Mr. Rujapong Prabhasanobol | Independent Director, Chairman of the Audit Committee |
|----|----------------------------|---|

Others Attending the Meeting

- | | | |
|----|-------------------------|---|
| 1. | Mr. Terapun Petchsuwan | Legal Consultant from The Far East Law Office (Thailand)
Company Limited |
| 2. | Mr. Werawus Churussamee | Legal Consultant from The Far East Law Office (Thailand)
Company Limited |

Before the Meeting Started:

Miss Chonticha Pumpreuk delivered a welcome speech to shareholders to the Extraordinary General Meeting of Shareholders No. 1/2019 of E for L Aim Public Company Limited and clarified the vote casting and counting procedures to shareholders, as follows:

- 1) Shareholders may cast their votes of approval, disapproval or abstention in ballots received at the time of registration before voting.
- 2) When the Chairman of the Meeting notified shareholders to pass the resolution in each session thereof, shareholders who intended to cast votes of disapproval or abstention would be requested to show their hands and to hand over the signed ballots to the Company's staff; whereas, the Company would count only votes of disapproval and abstention of shareholders, then, the number of such votes of disapproval and abstention shall be deducted from the total number of votes of shareholders attending the Meeting and having the voting rights, then, the remaining votes shall be regarded as votes of approval in such sessions; whereby, Miss Chonticha Pumpreuk shall be obliged to notify the results of voting in each session thereof to all meeting participants.
- 3) Vote counting method: One share shall be equal to One vote; and for transparency in counting of votes, the Company has assigned Mr. Werawus Churussamee to witness the counting of votes.
- 4) In this Meeting, the meeting agenda was proposed to the Meeting for consideration and approval with different proportions of votes of shareholders as per the requirements and the related laws. Therefore, Miss Chonticha Pumpreuk clarified to the Meeting regarding the total votes required for passing of resolution in each agenda, and asked for cooperation from shareholders to consider details of the meeting agenda from ballots received from the Company's personnel upon registration, and, also requested shareholders to consider and clarify the total votes required for passing of resolution in each agenda.
 - Resolutions in Agenda 1 and Agenda 3 must be passed with the majority votes of shareholders attending the Meeting and having the voting rights.
 - Resolutions in Agenda 2 must be passed with at least three-fourths of the total votes of shareholders attending the Meeting and having the voting rights; and
- 5) Any shareholder wishing to make inquiries or to express opinions was requested to make inquiries or to express opinions relating to such Session directly; and any shareholder wishing to give recommendations or other opinions not relating to such Session may express opinions in Session 10 "Consideration of Other Matters". Provided that any shareholder wishing to make inquiries or to express opinions was requested to clearly specify name and surname so that the Company shall record such information in the Minutes of the Meeting correctly and completely.
- 6) In case, shareholders additionally attended the Meeting after the start of the Meeting, shareholders or proxies may exercise their voting rights only in Sessions that they attended and resolutions thereof have not yet been passed; whereas, the Company's personnel shall report the number of shareholders and voting shares to the Chairman of the Meeting before the passing of resolutions.
- 7) After the conclusion of the Meeting, the Company asked for shareholders' cooperation to return ballots to the staff of the Company.

At 09.30 a.m., there were 72 shareholders attending the meeting by themselves, representing 2,315,481,021 shares, and 46 proxies, representing 14,791,448,444 shares, totally 118 shareholders, representing 17,106,929,465 shares or equal to 53.0993% of the total Paid-up Stock of the Company (the total Paid-up Stock of the Company was 32,216,851,992 shares)

The Meeting Started:

Mr. Preecha Nuntnarumit, the Chairman of the Meeting, addressed to the Meeting that, the shareholders attending the meeting, constituting the quorum; therefore, the Chairman of the Meeting addressed to start the Meeting as per the following agenda:

Agenda 1 To consider adopting minutes of the 2019 Annual General Meeting of Shareholders.

The Chairman of the Meeting proposed the matter to the Meeting to consider and adopt the Minutes of the 2019 Annual General Meeting of Shareholders convened on 22 April 2019. The Company has submitted copy of the minutes of the meeting to the Stock Exchange of Thailand according to Public Law. The minutes were also posted on the Company website and delivered to all shareholders, together with the Invitation for Shareholders' Meeting, Details as per Enclosure 1.

The Chairman of the Meeting provided all shareholders with opportunities to make inquiries.

Miss Chonticha Pumpreuk (Master of Ceremony) reported that, in this Agenda, the number of shareholders attending the Meeting has increased by 7 persons, representing 14,308,403 shares, from the start of the Meeting; as a result, there were totally 125 shareholders attending the Meeting, representing 17,121,237,868 shares.

Resolution The Meeting passed its resolution to adopt the Minutes of the 2019 Annual General Meeting of Shareholders, as proposed by the Chairman of the Meeting with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
Share	17,121,237,868	-	-	-
Percentage	100.0000	-	-	-

Agenda 2 To consider and approve the increase of the Company's registered capital of Baht 604,065,974.85 from the registered capital of Baht 2,577,488,835.45 to Baht 3,181,554,810.30 by issuing 8,054,212,998 ordinary shares with a par value of Baht 0.075 each, and the amendment to Article 4 of the Company's Memorandum of Association in accordance with the capital increase.

The Chairman of the Meeting: The Company has to issue share capital (fund raising) to make the payment for its commitment of Baht 200 million to reduce cost of debt and to do the debt restructuring of the Group of the Company. For the remaining of fund raising of Baht 202

million, the Company has a plan to invest in the project relating to its business and for utilising working capital. The objective to raise fund is to manage the financial structure as appropriate and expand its business.

Referring to the increase share capital to private placement in 2018, the objective was to reduce risk to have the negative equity attributable to the Company's shareholders and to solve the issues of high debt to equity ratio. There also was a plan to solve problem of subsidiary, WCI Holding PCL ("Wuttisak group"). The increase share capital in 2018 was received a good cooperation from investors.

As the problems of Wuttisak group need to take a long time to be solved, it may still have the risk to consider for the provision to be provided.

Medical device business is still growth and making profit and it has been contacted by other partners to cooperate to do the business. As the Company currently lacks of working capital and loss confidence from customers and suppliers about the financial status, management and board of directors agree that the Company needs to raise fund by issuing share capital to solve the issues as aforementioned. The purposes of increase capital are:

1. To reduce the Company commitment resulting in the negative impact of the Company directly affects to the medical device business, the Company needs to increase share capital to make the payment for the Company commitment to build the confidence and credibility with customers, financial institutions and alliances.

2. To use for working capital and invest in other business. As the Company has been contacted to be the distributor of new products (brands) together with interesting in the investment in a good relating business, the working capital is needed to do the business.

Management and board of directors consider and expect that the Company will have the benefits from this increase newly capital as follows:

- 1) The Company is able to solve the lack of confidence problem and build the credibility of medical device business which has the potential to be grown up and make the profit.
- 2) The Company is able to create an opportunity to explore new partnerships to expand the business into the manufacturer and distributors of new products to increase revenues. The Company expects that if it can be solved the confidence and credibility problems, the Company will make the revenues from Baht 1,800 million to Baht 2,500 -3,000 million per year in the near future.

To propose the shareholder meeting to consider and approve the increase of the Company's registered capital of Baht 604,065,974.85 from the registered capital of Baht 2,577,488,835.45 to Baht 3,181,554,810.30 by issuing 8,054,212,998 ordinary shares with a par value of Baht 0.075 each. The detail is presented in F53-4 and documentation will be sent together with invitation

letter no. 2. To comply with the relating business law, in case of the increase the registered capital, the Company will amend Article 4 of the Company's Memorandum of Association in accordance with the capital increase as follows:

4. Registered capital	Baht 3,181,554,810.30
Divided by	42,420,730,804 shares
	Baht 0.075 per share
Ordinary share	42,420,730,804 shares
Preferred share	None

For the purpose of good order in effecting registration of the amendment of the Articles of Association which might require revision of words or statements in the Articles of Association no. 4 and/or in the registration documents specified by the Department of Business Development, Ministry of Commerce in order to be in line with the resolution of the Meeting of Shareholders, and any order, suggestion or opinion of the registrar of the Department of Business Development, Ministry of Commerce, or officers of other relevant authorities, the Board of Directors proposed that the Extraordinary General Meeting of Shareholders no.1/2019 consider and approve the delegation to the authorized directors of the Company and/or any persons assigned by authorised directors to do any necessary acts for the purpose of accomplishing the amendment of the Articles of Association no. 4.

The Chairman of the Meeting: provided all shareholders with opportunities to make inquiries.

Patchara Kaewnukul (a shareholder) This issuance increase share capital of 8,054,212,998 units with proposed price at Baht 0.05 per share whereas the marketing prices is Baht 0.04 per share. Is it correct?

The Chairman of the Meeting: Yes, it is. The Company issued increased share capital of 8,054,212,998 units with proposed price at Baht 0.05 per share due to the expectation cash received of Baht 402 million.

Patchara Kaewnukul (a shareholder) Referring to the issuance increased share capital with the offered price at Baht 0.05 per share, the Company will receive cash of Baht 400 million. What is the Company's plan for using the increased share capital?

The Chairman of the Meeting: The Company has a plan to utilise cash in 2 sections:

1. To pay for the Company's commitment of Baht 200 million
2. For the remainder of Baht 202 million, the Company will has a plan to utilize cash for business expansion both of distributor and manufacturer to increase future revenues.

Patchara Kaewnukul (a shareholder) The medical device business normally imports product for sales which will be granted the credit terms from suppliers. What is reason of the Company to invest in this business?

The Chairman of the Meeting: As the Company is the distributor of various medical devices imported for sales, the payment condition for each supplier is different depending on the credit term to be granted from each supplier. Whereas the major customers of the Company are government sectors which will have the process to purchase products, starting from bidding, price inspection, making the agreement and providing 3-6 months credit term to customers or late payment from some government customers, the collections will take long time to be received. The Company also has to maintain inventory to serve customers. The aforementioned are reasons of the Company needed working capital for doing the business.

Patchara Kaewnukul (a shareholder) questioned is if the Company has fund of Baht 200 million, what the figure of revenue and gross margin should be.

The Chairman of the Meeting: The gross margin of medical device business normally is 30-35% and 15-20% for big project. The average gross margin of this industry is 30% of sales. If the increase share capital is not successful, the expected revenue of this business should be Baht 2,200-2,500 million.

Kumpon Kathapassa (a shareholder) Due to the allotment of new ordinary shares to existing shareholder at the ratio of 4 existing shares to 1 newly issued share with the offered price at Baht 0.05 per share whereas the market price is Baht 0.04 per share, if the raise fund in this time is not successful, what the plan to solve this problem.

The Chairman of the Meeting: Before Board of director passed the resolution to increase share capital and allot new shares to existing shareholder, management has already discussed this matter with the major shareholders of the Company. The major shareholders inform their intentions to the Company to subscribe their right. The pro rata basis (Right Offering) at the ratio of 4 existing shares to 1 newly issued share with the offered price at Baht 0.05 per shares are considered with the following reasons:

1. Board of directors is confident that the medical device business is still growth and has greater potential for profit.
2. The subsidiary, Wuttisak group, made loss and will be provided for the provision which has a risk to bring in the negative equity. The Board of directors; therefore, considered to increase share capital to protect the risk of negative equity. Referring to the offered price of Baht 0.05 million, if this raise fund is successful, the Company will be able to make the payment for its commitment and get the solution for liquidity issues. The Company will have the opportunity in its business and has better operating performance resulting in the stock price will be at par value.

Patchara Kaewnukul (a shareholder) After receiving funding, what the profitability should a business make.

The Chairman of the Meeting: Referring to the SET / SEC regulation, the Company is unable to inform the expected profit margin. However, the gross margin of medical device business of this industry normally is 30-35% and net administration expenses and financial cost will be 10-15%. The Company expected revenue approximately Baht 2,000 million per year and will be increased to Baht 3,500 million. The medical device market is currently growth from the policy of government i.e. improve and expand small urban hospital from 30 beds to 60 beds, 60 beds to 90 beds, and 90 beds to 140 beds. It also increases ICU rooms, operation rooms. As Thailand is going into aging society, public and private sectors will have the budget to support quality of life in older people. The Company expects that medical device businesses still have a potential growth and the Company has an intention to maintain reputation and to make the revenue of Baht 3,000 million in the near future.

Patchara Kaewnukul (a shareholder) In case the Company is able to reduce debts of Baht 200 million, what benefit of the Company to be received.

The Chairman of the Meeting: Short term loans and Long term loans of the Company are Baht 800 million. The Company has had the policy to reduce cost of debts for which this increase share capital will be able to comply with the policy and solve the liquidity problem of the Company as well.

Thitipong Sophonudomporn (a shareholder) questioned as follows:

1. After paying the commitment of Baht 200 million, what the plan of the Company to make the payment of short term loan.
2. Referring to the remaining funding of Baht 200 million (net with commitment payment) is for investing in medical device business, what the plan to make the profit from this investment next year. If not, how long does the Company take to make the profit from this investment?
3. What is performance of Wuttisak group? Will Wuttisak group need to provide for the provisions? If it will need to provide, how much of the provision is. Are there any plans to sell WCIH shares and what the plan to do?

The Chairman of the Meeting:

1. The Company expects to receive funding from this increase share capital of Baht 402 million. After making the payment for commitment of Baht 200 million, the Company will need to make the payment for short term loan as usual.

2. For the remaining funding after making the payment for commitment of Baht 200 million, the Company has a plan to invest in medical device business as the Company expects that the medical device business still has the potential growth and making profit. Therefore, the Company strongly believes that the investment of Baht 202 million in medical device business is the most benefit of the Company.

The Company has already invested in Clean room and also will have a plan to invest in AED resulting in increasing in revenue.

In addition GE Health Care Pte. Ltd. agreed with the Company to make the Picture Archiving and Communication System and has been signed MOU. The Company has been also appointed as the distributor of Ultrasound Scanner. Unfortunately, all processes need funding to operate. As the Company has been contacted to be the distributor of various products and government sector and private sector also have the plan to promote medical devices business, the Company believes that if the increase share capital is successful, the medical device business will rapidly growth.

3. For Wuttisak group, it still has made the loss performance and will have the potential risk to be provided for the provision which is currently unable to quantify the provision figure. However, the group of the Company attempts to reduce the provision loss as much as possible. The purpose of this increase share capital is to increase financial position of the Group of the Company and further expand the medical device business. For the policy relating with Wuttisak group after the increase share capital, the Company will have the policy to not support any financial operation to Wuttisak group.

Dr. Wiset Tantini (a shareholder) Is this increase capital for debt payment incurred from acquired Wuttisak?

The Chairman of the Meeting:

Before acquired Wuttisak, the Company does not have any loans. This increase capital is for debt payment from investing in Wuttisak and the Company expects that all debts will be repaid by 2021.

Dr. Wiset Tantini (a shareholder) The market price of EforL still decrease of which the current price is at Baht 0.03 per share. It may be incurred from economic situation as every stock price is decreased as well i.e. property business. However, I suggest that the Company should solve the C Caution symbol which may be the reason for the lower price. Another reason is management does not do the public advertisement and communication.

As fully experienced in medical sectors and many relationships with medical people, Thailand society currently is in the aging society and has many older people. The government sector also supports the budget in medical sector. For example, I am 80 years old and has huge

amount of medical expenses. Therefore, I believe that the Company has an opportunity to make the profit.

I also suggest that the Company should improve to increase the advertising product to motivate financial institution and major shareholder to confident in business and put more investment in the Company. This will result to increase the market prices.

The Chairman of the Meeting:

1. Referring to current price at Baht 0.03 -0.05 per share, the board of director has an intention to operate business to make profit to reflect the stock price. In addition the Board of director believe that the group of Company will be turnaround to have a good performance. In addition the provision of subsidiary will be lower amount provision to be provided and reversed into the positive performance. I am also confident that the performance of the Company will be improved and its financial position will be stronger.
2. For Advertising issues, the Company does not focus in advertisement because the Company focuses to directly sell to target customer. The Company has an opening event for new product, blood analysis, under brand Dirui which has invited doctors, nurse and medical people to join. The Company always makes the marketing in this way and strongly believe that EforL has well-known in medical business.

Sakchai Sakulsirmonri (a shareholder) questioned that after increase capital to pay commitment of Baht 200 million, How much debts of the Company and when it will be pay off.

The Chairman of the Meeting: Loans from banks should be paid by 2021.

Sakchai Sakulsirmonri (a shareholder) What is the Debt to Equity ratio of the Company?

The Chairman of the Meeting: The Debt to equity ratio is not over than 6 times which is high. After paying debts, it should be decreased to 4 times.

Sakchai Sakulsirmonri (a shareholder) After paying debts of Baht 200 million, Debt to Equity Ratio is still high.

The Chairman of the Meeting: It expects to be improved and all outstanding loans will be paid by 2021.

Sakchai Sakulsirmonri (a shareholder) Referring to Khun Wichai Tongtang, held shares at 22%, if Khun Wichai over-subscribed, it will be over 25% resulting in tender offer process. Am I correct? If the Company has to do the tender offer, it should be prepared many process i.e. valuation, appoint financial advisor which also have the huge expenses.

The Chairman of the Meeting: The Company has determined that if there is any shareholders over-subscribed and has a trigger to do the tender offer, the Company and shareholders need to comply with all regulation.

Sakchai Sakulsirmonri (a shareholder) As the fully experienced shareholder, I am worried that many underperformed or loosed company always increase or decrease capital by decrease par or combine par of which these tools are unfair with non-controlling shareholders. It should not happen with the Company (EforL).

The Chairman of the Meeting: The Company will consider and not to apply with this suggestion. As the Q2/2019 the equity attributable to the Company's shareholders has Baht 561 million which is less than 50% of paid up capital, equivalent to Baht 926 million, the Company still has been remarked C "(Caution). We have been asked from a shareholder last time relation to the issuance newly share capital for which we are not ensure for the issuance. As we have considered that the financial position to reduce risk of the negative equity attributable to the Company's shareholders, commitment and working capital, we will propose to increase newly share capital.

Sakchai Sakulsirmonri (a shareholder) questioned that how much of the equity attributable to the Company's shareholders before and after increase share capital are.

The Chairman of the Meeting: The equity attributable to holders of parent in Q2/2019 is Baht 561 million.

Sakchai Sakulsirmonri (a shareholder) According to the plan to solve "C" Caution, the Company needs to have the equity attributable to the Company's shareholders not less than 50% of paid up capital of which the paid up share capital is Baht 2,400 million. Therefore, the equity of Baht 926 million which is still not reached 50%.

The Chairman of the Meeting: The equity of Baht 926 million is accounted to 50% of paid up capital net with discount on share capital, which is Baht 1,850 million. The calculation rules need to deduct the discount on share capital.

Sakchai Sakulsirmonri (a shareholder) Referring to the discount on share capital, this offered price is Baht 0.05 per share but par value and discount on share capital are Baht 0.075 per share and Baht 0.025 per share, respectively. What is the plan to manage the discount and loss?

The Chairman of the Meeting: For above question, the market price is Baht 0.04 per share whereas the offered price is Baht 0.05 per share because the management believes that after this increase capital, the Company will have good performance and the impairment to be lowered than expected or reversed. These will bring the price to par value. Therefore, the offered price of Baht 0.05 per share is considered at the discount rate of 30% which is fair price. In addition if the offered price is Baht 0.04 per share, the market price may be lower than Baht 0.04 per share.

Sakchai Sakulsirmonri (a shareholder) questioned for the average gross margin of medical device business.

The Chairman of the Meeting: The average gross margin of medical device business is 30%-35%.

Sakchai Sakulsirmonri (a shareholder) Referring to the competitor, how much of sales of competitor are. I understand that EforL is the only one distributor of medical device business listed in the SET.

The Chairman of the Meeting: If the same medical device products, EforL is only one distributor listed in the SET. For other companies listed in the SET, for example, Berli Jucker, will sell X-ray machine whereas EforL will focus to sell medical devices using in operation room and ICU.

The Chairman proposes the meeting to consider and approve the increase of the Company's registered capital and the amendment to Article 4 of the Company's Memorandum of Association in accordance with the capital increase.

Miss Chonticha Pumpreuk (Master of Ceremony) reported that, in this Agenda, the number of shareholders attending the Meeting has increased by 33 persons totaling of 106,771,015 shares resulting in the total shareholders to 158 people representing 17,228,008,883 shares

Resolution

The Meeting passed its resolution to the increase of the Company's registered capital of Baht 604,065,974.85 from the registered capital of Baht 2,577,488,835.45 to Baht 3,181,554,810.30 by issuing 8,054,212,998 ordinary shares with a par value of Baht 0.075 each, and the amendment to Article 4 of the Company's Memorandum of Association in accordance with the capital increase, with the votes as follows

	Approval	Disapproval	Abstain	Voided Ballot(s)
Share	17,226,883,417	825,466	300,000	-
Percentage	99.9952	0.0048	-	-

Agenda 3

To consider and approve the allotment of new ordinary shares to existing shareholder on a pro rata basis (Right Offering) at the ratio of 4 existing shares to 1 newly issued share.

The Chairman of the Meeting. Pursuant to the agenda 2 which the Meeting has passed the resolution to increase share capital, the Company has to allocate the increase share capital not more than 8,054,212,998 shares with the par value of Baht 0.075 per share. The Meeting will consider the below detail:

1) The issuance and offering of ordinary shares to **the existing shareholders** of the Company on a pro rata basis (Right Offering) at the ratio of 4 existing shares to 1 newly issued share (at

par value of Baht 0.075). Any fraction of shares shall be disregarded. The offering price is Baht 0.05 per share (Five Satang).

2) The existing shareholders have the rights to oversubscribe pursuant to his/her existing entitlement. If there are newly issued ordinary shares left from the first of allotment, such shares will be allotted to each existing shareholder over-subscribing than his/her entitlement in proportion to his/her existing ordinary shares. Newly issued shares will be allotted until there is no share left from the allotment or until there is no shareholder who subscribe for the share.

The Company has specified Record Date for the right to subscribe the newly issued ordinary shares from Right Offering on 12 November 2019 and the date of subscription and payment for the newly issued ordinary shares during 2, 3, 4, 6 and 9 December 2019 (total of 5 business days).

In the case that the allotment of oversubscribed newly issued ordinary shares enable any oversubscribing shareholders to hold the Company's shares in an increasing nature reaching or crossing the point where a tender offer must be made, as prescribed in the Notification of the Capital Market Supervisory Board No. TorChor. 12/2554 Re: Rules, Conditions, and Procedures for the Acquisition of Securities for Business Takeover, the said shareholders must act according to the laws. However, the allotment of shares, in any case, must not violate the foreign limit as specified in the Company's Articles of Association which allow the foreign shareholding of not exceeding 49% of total issued shares of the Company.

In addition the Company would like to propose the Meeting to consider and approve to delegate the power the Board of Directors of the Company and/or Chief Executive Officer to be empowered to do all acts and things as deemed necessary and appropriate with regard to the issuance and offering of newly issued shares as well as amending any details and condition as deemed necessary and/or related to an issuance and/or allotment of newly issued shares under the condition of related laws with including but not limited to method of allotment of newly issued shares, specification of subscription period and payment of newly issued shares and etc. and empowered to do all acts as deemed necessary and appropriate with regard to an issuance and allotment in order to complete the issuance and allotment of newly issued shares with including but not limited to providing information, contacting, preparing, signing, delivering, submitting any documents, applications in relation to the issuance and offering to Securities Exchange Commission, Stock Exchange of Thailand, Thailand Securities Depository Company Limited, ministry of Commerce and other related authorities as well as request for approval for the newly issued ordinary shares to be listed on the Stock Exchange of Thailand as well as entrust other person to be authorized etc. The detail of the allocation of Newly-Issued Ordinary Shares will be present in F53-4 (Enclosure 2).

The Chairman of the Meeting: Opened session for shareholders to ask questions as follows.

Patchara Kaewnukul (a shareholder) questioned that if the issued and offered the increased share capital is incomplete, what the legal effect will be.

The Chairman of the Meeting: Although the issued and offered the increased share capital is in complete for example the subscription right is approximately 50-60%, the Company is able to process to register share capital.

Songphol Pongpattankarn (a shareholder) In case of the issued and offered the increased share capital is not success whether the Company will still have a plan to re-increase share capital or not. I believe that if this increase shares capital is incomplete, the Company will increase share capital again. I also suggest the Company should consider selling shares in Wuttisak group.

The Chairman of the Meeting: For the question to re-increase share capital, we are unable to answer the questions right now.

For selling shares of Wuttisak group, management try to manage the business and sell shares of Wuttisak group to reduce loss. The negotiations with investors, Korea, Japan, Singapore, are still unable to conclude due to the pricing issues. The management also attempt to seek out new investor in Global to join in the business with the appropriated pricing. As the parent company of Wuttisak group, the Company tried to help the subsidiary to solve the problem and provided the financial support by investing in the beauty business from funding from private placement. However, the Company currently has a policy to not support funding to subsidiary and notified them to solve its financial problems by themselves by recruiting the professional management to solve this situation. The major shareholders have also been confident in the beauty business and management of subsidiary has intention to solve the problems and turn around business. It will affect to the reversal impairment or decrease their provision. However, this increase share capital will make the Company to have strong in financial position.

Songphol Pongpattankarn (a shareholder) questioned on the offered price of PP and they are currently still held their share or not.

The Chairman of the Meeting: The offer prices at that time are Baht 0.04 per share and all PP investors still hold their shares.

Songphol Pongpattankarn (a shareholder) After increasing and issuing share capital to Private placement, the share price at that time was increased to Baht 0.11 whereas the current price is going down to Baht 0.04 per share. According to this increasing share capital at Baht 0.05 per share, minor shareholders are uncertain to subscribe because they are not confident in the share price. Referring to the increase share capital to RO last time which was not success, the offering price was Baht 0.14 per share due to the shareholders were not confident in the

financial performance as well. It should be notifying the information to shareholders to confident in the Company operation.

The Chairman of the Meeting The shareholders should be confident by considering operating performance of parent company, medical devices business. If the shareholders considered the operating performance for last two years, the separated financial performance had net profit of which the Company strongly believes that the medical device business still has the potential business and will be able to make the repayment for all debts. It also will be the number one of medical device business in Thailand with expected revenue of Baht 3,000-4,000 million of which the results will be reflected to the stock price.

Songphol Pongpattankarn (a shareholder) questioned on the plan to solve Wuttisak problems.

The Chairman of the Meeting Board of directors and management attempt to solve its problems to turnaround the business which may be improved in Mid-year 2020.

Songphol Pongpattankarn (a shareholder) questioned on whether the Company have power of control management in Wuttisak or not.

The Chairman of the Meeting The Company is currently held 56% in Wuttisak group and controlling its business as the major shareholders. According to the SET/SEC regulation, the Company considers good corporate governance guides to supervise its subsidiary and preparing the consolidated financial statements. The Company has a plan to solve the problems and manage subsidiary because the Company has to recognize financial performance of Wuttisak group.

Songphol Pongpattankarn (a shareholder) Thank you for your clarification. In my point of view, I still have confident in the Company but I am sure that the Company may re-increase share capital as this time will not receive 100% capital funding.

The Chairman of the Meeting The Company does not intend to disturb the shareholders with the increase newly share capital. If the Company has to increase share capital, we will consider reducing the effect with all shareholders.

Dr. Wiset Tantinipankul (a shareholder) As shareholder of the Company, following news of the Company, recognized that the medical device business has positive performance, I suggest the Chairman to report its business to all shareholders.

The Chairman of the Meeting The Company is the distributor of various brands in world class for example:

1. GE Health Care: Anesthesia System, Incubator & Radiant Warmer
2. SIEMENS: Blood analysis
3. Nihon Kohden, Japan: Automated External Defibrillator (AED), Defibrillator
4. Hamilton Medical: Transport Ventilator

5. VYAIR MEDICAL: Pulmonary Function Test or Lung Function Test, ultrasound

Most hospitals realized that EforL is distributor of quality product, good services teams in 24 hours and sales teams have certificates and fully experienced in medical business. Due to world innovation technology is developed particular in China, it has good technological innovation in medical business with good quality products with fair price. To expand business in the middle market, the Company is considering being the distributor of medical products from China. However, I confirm that the Company is currently the distribution of good quality medical device product with having good service customer service reputation recognized by medical people.

Methee Unadirekul (Proxy) The increase share capital in this time is quite difficult to success because it offers to existing shareholder (RO) which is still uncertainly to expect how much of shares subscribed by major shareholder. In addition minor shareholders are worried and focused in share prices. The Company also informed us that the purpose of this increase share capital is for debt payment of Baht 200 million. If the funding is not reached Baht 200 million, what the plan is.

The Chairman of the Meeting The Company expected to receive funding over Baht 200 million. If not, the Company will negotiate with lender for extend payment period.

Nara Sripeth (a shareholder) questioned on how much of investment value and impairment in Wuttisak.

The Chairman of the Meeting The Company invested in Wuttisak of Baht 4,500 million by debt financing of Baht 1,400 million. The impairment is currently of Baht 2,600 million. However, if there is operation in CLMV, the provision of international expansion of Baht 523 million might be reversed which will be the positive impact with the Company.

Mr. Pattaraphong Ketthong (a shareholder) The average market price is Baht 0.03 per share which is quite low. The Company currently focuses only on the medical device business whereas the Company operations have both of medical device and healthiness. My suggestions are as follows:

- 1) The Company should review business plan by focusing on healthiness because the Company has not yet operated healthiness products which there are currently new product innovations about healthiness i.e. smart watch.
- 2) For the funding of Baht 200 million, in my personal view, I think that this fund is not enough for solve the problems; debt payment and business expansion because there are several risks from economic crisis next year. Does the Company evaluate any mistakes?
- 3) I suggest the Company to review source of profit both of domestic and overseas and evaluate the capacity to compete with competitors.

4) For the beauty business, Wuttisak group, it is quite difficult to manage its business into positive performance due to a few customers. I recommend the Company to increase other services i.e. body services and some services using small equipment.

5) The Company should review business plan to increase maintenance services and using Artificial Intelligence (AI) for useful benefit.

The Chairman of the Meeting The Company currently has subsidiary company, Spacemed Co., Ltd., distributor of small medical device, i.e. Blood Pressure Monitor, Nasal Continuous Positive Airway Pressure, Blood Sugar Meters.

Mr. Pattaraphong Ketthong (a shareholder) I suggest the Company should plan to be the distributor of Robot for look after patient and older people.

The Chairman of the Meeting The Company has 2 businesses as following:

Medical devices: the Company focuses to be the distributor of medical device using in the operation room, intensive care unit (“ICU”), and providing after sale services. Service income from last year was approximately of Baht 120 million.

The Company has a business plan to expand its business into the manufacturer of medical device using the innovation and will register such innovation into the name of Company. For the medical device of older people, it is included into our business plan. The Company has also intended to increase capability of the current business and expand market.

For small medical device equipment, Spacemed is the distributor and managed by Khun Jackrit Lohacharoensup. Spacemed currently expands market by appointing other distributors of small home use products; electronic blood pressure monitor, weight scale, blood glucose monitors, via online cooperate with True Corporation PCL.

Beauty business, Wuttisak group: Management and board of director consider that beauty business are quite the same services and unable to do the advertisement due to the regulation. Therefore, management seeks out another business, Wuttisak Cosmetic Inter Co., Ltd., skin care distribution and no any regulation to do the advertisements. It has launched new products including Snail 8, premium product, under Siam Snail Co., Ltd.

In 2019, Wuttisak Cosmetic has used Korean actor as the presenter and opened beauty center at BTS station as flagship of beauty business. Management realized that the mistake investment in beauty clinic is the regulation to do the advertisement. Wuttisak has faced the problems and paid fines. However, thank you for shareholders for questions and advice.

Dr. Wiset Tantinipankul (a shareholder) Referring to the advice from other shareholders relating to review the business plan and increase medical products, I think it is a good opportunity of the Company as Thailand is going into the aging society. If the Company has a limited investment, it should find out business partner to join the business.

The Chairman of the Meeting The Company went to business trip in China, Chienghai, to observe medical device factory. The Company is considering being the distributor or joint venture to manufacture its medical device.

Dr. Wiset Tantinipankul (a shareholder) The Company should focus to negotiate with investor to join into the business to create value of firm.

The Chairman of the Meeting Thank you all of you and propose the meeting to consider and approve the allotment shares offering to existing shareholders (Right offering) at the ratio of 4 existing shares: 1 new share

Miss Chonticha Pumpreuk (Master of Ceremony). In this Agenda, there were 1 additional shareholder attending the Meeting, representing 133,300 shares; as a result, there were totally 159 shareholders attending the Meeting, representing 17,228,142,183 shares.

Resolution

The Meeting passed its resolution to approve the allotment of new ordinary shares to existing shareholder on a pro rata basis (Right Offering) at the ratio of 4 existing shares to 1 newly issued share, with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
Share	17,227,666,717	175,466	300,000	-
Percentage	99.9990	0.0010	-	-

Agenda 4

Other Matters (if any).

The Chairman of the Meeting addressed to thanks all shareholders for their devotion of time to attend the Meeting, and addressed to close the Meeting.

The Meeting was concluded at 11:30 a.m.

(Signed)



Chairman of the Meeting

(Mr. Preecha Nuntnarumit)

Chairman of the Board of Directors